FDA Approves Decnupaz, the First CD123-Targeting ADC for a Blood Cancer With Historically Dismal Prognosis
AbbVie's pivekimab sunirine-pvzy wins FDA approval for BPDCN on May 27, with a 69.7% complete remission rate in newly diagnosed patients and the first-ever outpatient initiation for this ultra-rare malignancy.
5 min read7 sources